Verge Labs has rebranded as an AI-focused company building computational models from 12,000+ human brain samples to predict drug efficacy and identify optimal patient populations before clinical trials. This approach addresses a fundamental failure mode in drug development: testing the wrong target in the wrong patients.
Key Points
- AI models trained on largest proprietary human brain tissue dataset assembled
- Virtual biopsy concept reconstructs brain biology from blood and imaging alone
- Precision neurology aims to replicate oncology's shift to patient-matched therapies
Longevity Analysis
The ability to model disease progression at the individual level—rather than relying on population averages or animal models—represents a shift toward truly personalized intervention. By reconstructing what is happening inside the brain without direct tissue access, this platform could identify which patients will respond to a given treatment and which will not, reducing wasted exposure to ineffective therapies while accelerating access to beneficial ones. For longevity medicine, this precision is essential: the difference between a treatment that works for your neurobiology and one that does not often determines whether you maintain cognitive function, neuroplasticity, and quality of life over decades.
Original published by Longevity.Technology, by Kyle Umipig.